📈 Jumpstart Signal Watchlist — August 24, 2026

🏢 What they do: MeiraGTx Holdings plc is a clinical-stage genetic medicines company that develops gene therapies and other genetic medicine platforms for both rare and more common diseases. Its work includes programs in eye diseases, Parkinson’s disease, and radiation-induced dry mouth, along with its riboswitch technology for controlled delivery of biologic therapies.
- 🎯 Current $14.83 is 1% below 3yr high $14.97 · ⏳ SMA200 $9.45 (current price $14.83 is above) · 💰 Market Cap $1.4B
- MGTX shows decent technicals supported by positive sentiment.

💎 Quality (Q): 38/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 456% (>20%); PEG ratio 0.05 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA21 (10.7%)
- 🔔 Strong above EMA50 (18.9%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 68 showing strength
📢 Sentiment (S): 7/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ MeiraGTx (NASDAQ:MGTX) Trading 8.4% Higher Following Strong Earnings — MarketBeat.
🤖 The article highlights a major earnings beat, with EPS and revenue both far above expectations, alongside clinical and regulatory progress. It is positive for MGTX because the results and pipeline updates strengthen both near-term sentiment and long-term prospects.
✅ MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank of Canada — MarketBeat.
🤖 RBC raised its price target and kept an outperform rating after the company’s strong quarter. A higher target and maintained bullish stance are supportive for the stock.
❌ MeiraGTx (NASDAQ:MGTX) CFO Richard Giroux Sells ... — MarketBeat.
🤖 This piece reports insider selling by the CFO, which can weigh on sentiment. Although it also mentions a narrower loss and a positive analyst backdrop, the insider sale is the main stock-negative takeaway.
⚪️ MeiraGTx Holdings PLC (NASDAQ:MGTX) Given Average Rating of Moderate Buy by Brokerages — MarketBeat.
🤖 The article mainly summarizes existing analyst coverage and target prices rather than new company developments. It is neutral because it reflects steady Street sentiment without a clear new catalyst.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Bioventus Inc. is a global medical device company that develops and commercializes clinically proven, minimally invasive products to relieve pain and address musculoskeletal challenges by enhancing the body's natural healing process .
- 🎯 Current $14.02 is 8% below 3yr high $15.26 · ⏳ SMA200 $9.36 (current price $14.02 is above) · 💰 Market Cap $948M
- BVS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 43/60
- 🏦 EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 327% (>20%); ROE 24% (>15%); Near-high ROE setup (52wk high + ROE); PEG ratio 0.06 (<1.5).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (12.6%)
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 9/10
- 🗞️ News sentiment is positive.
✅ Bioventus Q2 2026 slides: profits rise, strategic review underway — Investing.com.
🤖 Bioventus reported improved profitability, beat adjusted EPS estimates, and said it is reviewing strategic alternatives after receiving interest from potential buyers. Those developments are generally supportive for the stock because they point to stronger operating performance and possible corporate action upside.
✅ Bioventus (NASDAQ:BVS) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says — MarketBeat.
🤖 Canaccord Genuity raised its price target to $19 while maintaining a buy rating, reinforcing a bullish analyst view on the shares. The report also noted that recent quarterly EPS matched estimates, which helps support the positive tone.
⚪️ Bioventus (BVS) Q2 Earnings Meet Estimates — Yahoo Finance.
🤖 Bioventus reported quarterly EPS in line with expectations, which removes uncertainty but does not create a major surprise. The article is neutral overall because it describes a meet rather than a clear beat or miss.
🍭 Bonus (B): 0/10 — Surgical & Medical Instruments

🏢 What they do: Ooma, Inc. provides cloud-based VoIP phone systems and unified communications services for businesses and consumers, featuring voice, messaging, video, and AI tools like call transcriptions and answering services. Their primary offerings include Ooma Office for small to mid-sized businesses, Ooma AirDial for POTS line replacement, and Ooma Telo for affordable residential landline service.
- 🎯 Current $21.24 is 4% below 3yr high $22.14 · ⏳ SMA200 $15.26 (current price $21.24 is above) · 💰 Market Cap $582M
- OOMA shows decent technicals supported by positive sentiment.

💎 Quality (Q): 54/60
- 🏦 Low drawdown (14.2% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 1000% (>20%); Revenue growth 25% (>15%); Low LT D/E 0.50 (<1.0).
⏰ Entry (E): 0/20
- 📈 RSI at 53 in healthy mid-range
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Benchmark reiterates Ooma stock rating ahead of earnings — Investing.com.
🤖 Benchmark reaffirmed a Buy rating and raised its price target to $24, citing product growth and management’s improved outlook. That kind of analyst endorsement is favorable for $OOMA ahead of the upcoming report.
✅ Thryv and Ooma Announce Co-Marketing Agreement Targeting Small Businesses — Yahoo Finance / Business Wire.
🤖 Ooma announced a co-marketing agreement with Thryv to broaden awareness of its offerings among small and medium-sized service businesses. Partnerships like this can expand distribution and support future revenue growth.
⚪️ Globeflex Capital L P Makes New Investment in Ooma, Inc. Common Stock — MarketBeat.
🤖 This is a stock-ownership filing rather than operating news, and it signals institutional interest without changing Ooma’s fundamentals. The article also notes Ooma’s recent earnings beat and relatively strong analyst support, which is modestly supportive for sentiment.
🍭 Bonus (B): 10/10 — Computer Processing & Data Prep (Technology sector)

🏢 What they do: Exelixis is an oncology-focused biotechnology company that discovers, develops, and commercializes medicines for hard-to-treat cancers. Its main products include CABOMETYX (cabozantinib), COMETRIQ (cabozantinib), and COTELLIC (cobimetinib), and it also advances a pipeline of small molecules and biotherapeutics for cancer treatment.
- 🎯 Current $54.55 is 4% below 3yr high $57.10 · ⏳ SMA200 $46.76 (current price $54.55 is above) · 💰 Market Cap $13.6B
- EXEL shows favorable technicals but negative sentiment warrants caution.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 26% (>20%); ROE 47% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 2/20
- 📈 RSI at 53 in healthy mid-range
- ⚠️ SMA20/SMA50 bearish crossover
📢 Sentiment (S): 1/10
- 🗞️ News sentiment is negative.
❌ Exelixis Announces Second Quarter 2026 Financial Results and Provides Corporate Update — Business Wire.
🤖 Exelixis reported Q2 2026 results and lowered its 2026 revenue outlook, citing slower-than-expected growth in the neuroendocrine tumor indication. The earnings beat was offset by the guidance cut, which is typically negative for the stock.
❌ Exelixis (EXEL) Is Down 6.7% After Cutting 2026 Revenue Outlook Amid Oncology Investment Pivot — Yahoo Finance.
🤖 This article says EXEL fell after management cut full-year revenue guidance and increased investment in its pipeline. The market reaction and lower outlook make the piece negative for the stock.
⚪️ BMO Capital Markets Upgrades Exelixis (NASDAQ:EXEL) to "Hold" — MarketBeat.
🤖 BMO’s move brought its rating in line with the broader consensus hold view rather than signaling a stronger bullish stance. The upgrade to hold is neutral for EXEL because it does not materially improve the outlook.
🍭 Bonus (B): 10/10 — Biological Products (Biotech sector)

🏢 What they do: Concentra Group Holdings Parent, Inc. is a provider of occupational health services in the United States, focused on helping employers manage workplace injuries and employee health. Its services include occupational health centers, onsite employer clinics, telemedicine, workers’ compensation care, and other direct-to-employer health services.
- 🎯 Current $34.99 is 2% below 3yr high $35.53 · ⏳ SMA200 $24.45 (current price $34.99 is above) · 💰 Market Cap $4.5B
- CON shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (12.8% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 46% (>20%); ROE 42% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 0/20
- 🔔 Strong above EMA50 (11.0%)
- 🔔 VWMA trending up (5 consecutive days)
- 📈 RSI at 65 showing strength
📢 Sentiment (S): 10/10
- 🗞️ News sentiment is positive.
✅ Concentra Group Holdings Parent, Inc. Announces Results For Its ... — Business Wire.
🤖 Concentra reported second-quarter 2026 results, declared a cash dividend, and raised full-year guidance. That combination of an earnings beat, higher outlook, and capital return is favorable for the stock.
✅ Concentra Group Holdings Parent (NYSE:CON) Reaches New 12 ... — MarketBeat.
🤖 This piece highlights Concentra’s earnings beat, new 52-week high, and continued analyst support. It is positive because strong results and bullish price-target commentary can support investor sentiment.
✅ Concentra Group Holdings Parent (NYSE:CON) Sets New ... — MarketBeat.
🤖 The article focuses on the stock making another 52-week high after the strong quarterly report. It is positive because it reflects momentum driven by better-than-expected earnings and favorable analyst views.
🍭 Bonus (B): 0/10 — Specialty Outpatient Facilities

🏢 What they do: Cass Information Systems, Inc. provides integrated payment and information management services, specializing in auditing, processing, and paying high-volume invoices for freight transportation, utilities, telecom, waste, cloud, and facilities expenses.
- 🎯 Current $57.42 is 2% below 3yr high $58.54 · ⏳ SMA200 $46.67 (current price $57.42 is above) · 💰 Market Cap $735M
- CASS shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (7.4% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 23% (>20%); ROE 15% (>15%); Low LT D/E 0.00 (<1.0).
⏰ Entry (E): 3/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 6/10
- 🗞️ News sentiment is positive (mixed coverage).
✅ Cass Information Systems (NASDAQ:CASS) Reaches New 1-Year High - Time to Buy? — MarketBeat.
🤖 The article says CASS reached a new 52-week high and notes favorable analyst sentiment, including a Buy consensus and price targets above prior levels. It is positive for the stock because it reflects strong price momentum and continued supportive analyst coverage.
✅ Cass Information Systems (NASDAQ:CASS) Reaches New 52-Week High - Still a Buy? — MarketBeat.
🤖 The article highlights that CASS hit a new 52-week high and that analysts still broadly rate the stock a Moderate Buy. The mention of a dividend and continued upward momentum makes this modestly positive for the shares.
❌ Cass Information Systems (NASDAQ:CASS) Lowered to "Hold" Rating by Zacks Research — MarketBeat.
🤖 This piece reports that Zacks Research cut CASS from strong buy to hold. That downgrade is negative for the stock because it reduces analyst enthusiasm even though broader consensus remains constructive.
⚪️ Cass Information Systems, Inc $CASS Stake Reduced by Emmett Investment Management LP — MarketBeat.
🤖 The article focuses on an institutional investor trimming its position, which is not a direct operating update for the company. It is neutral overall because it does not change the underlying business outlook, though it may slightly weigh on sentiment.
⚪️ 53247 Shares in Cass Information Systems, Inc $CASS Bought by Commerce Bank — MarketBeat.
🤖 This filing-style article reports another institutional ownership change rather than new business performance or guidance. It is neutral for the stock because it mainly signals portfolio activity, not a direct change in fundamentals.
🍭 Bonus (B): 0/10 — Business Services

🏢 What they do: John Wiley & Sons, Inc. (Wiley) is a global research and learning company that publishes over 1,900 peer-reviewed scientific, technical, medical, and scholarly journals along with academic and professional books, encyclopedias, and digital content .
- 🎯 Current $53.20 is 4% below 3yr high $55.72 · ⏳ SMA200 $39.29 (current price $53.20 is above) · 💰 Market Cap $2.8B
- WLY shows decent technicals supported by positive sentiment.

💎 Quality (Q): 56/60
- 🏦 Low drawdown (11.0% max); EMA21 above EMA50; EMA uptrend sustained 5+ days; EPS growth 103% (>20%); ROE 26% (>15%); Low LT D/E 0.81 (<1.0).
⏰ Entry (E): 0/20
- 🔔 VWMA trending up (5 consecutive days)
📢 Sentiment (S): 8/10
- 🗞️ News sentiment is positive.
✅ Why John Wiley & Sons (WLY) Could Be 24 ... — Yahoo Finance.
🤖 This article highlights renewed attention on Wiley after it launched a spectral analysis API portfolio for labs, which could support longer-term revenue opportunities. Product expansion into scientific workflows is generally favorable for the stock.
✅ John Wiley & Sons (NYSE:WLY) Sets New 52-Week High — MarketBeat.
🤖 The piece says WLY hit a new 52-week high and also notes a slight earnings beat, which is supportive for sentiment. The dividend increase adds another positive catalyst for income-focused investors.
⚪️ John Wiley & Sons (NYSE:WLYB) Sets New 12-Month High — MarketBeat.
🤖 The article is positive on price action, but the underlying earnings mix was only mixed: EPS slightly beat estimates while revenue missed. That makes the news more balanced than strongly bullish.
⚪️ John Wiley & Sons (NYSE:WLYB) Trading 0.8% Higher — MarketBeat.
🤖 This is mainly a market-movement update that repeats Wiley’s modest EPS beat, revenue miss, and analyst hold stance. It does not add a strong new catalyst for the stock.
🍭 Bonus (B): 0/10 — Book Publishing